Adherex Technologies (NASDAQ:FENC) Director Rosty Raykov Sells 10,946 Shares

Adherex Technologies Inc. (NASDAQ:FENC) Director Rosty Raykov sold 10,946 shares of Adherex Technologies stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $6.31, for a total value of $69,069.26. Following the completion of the transaction, the director directly owned 113,856 shares in the company, valued at approximately $718,431.36. This represents a 8.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Rosty Raykov also recently made the following trade(s):

• On Monday, February 2nd, Rosty Raykov sold 10,349 shares of Adherex Technologies stock. The shares were sold at an average price of $7.76, for a total value of $80,308.24.

Adherex Technologies Trading Up 0.2%

FENC opened at $6.42 on Friday. The business has a 50 day moving average of $7.72 and a 200-day moving average of $8.01. The stock has a market capitalization of $221.30 million, a price-to-earnings ratio of -18.88 and a beta of 0.93. Adherex Technologies Inc. has a 1-year low of $4.68 and a 1-year high of $9.92.

Adherex Technologies (NASDAQ:FENC) last announced its earnings results on Friday, March 27th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.21). The company had revenue of $13.78 million for the quarter, compared to the consensus estimate of $14.75 million. Adherex Technologies had a negative return on equity of 183.18% and a negative net margin of 22.62%. Equities analysts predict that Adherex Technologies Inc. will post -0.11 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on FENC shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Adherex Technologies in a research note on Thursday, January 22nd. Piper Sandler assumed coverage on Adherex Technologies in a research note on Friday, January 9th. They set an “overweight” rating and a $18.00 price target on the stock. Wall Street Zen downgraded Adherex Technologies from a “strong-buy” rating to a “buy” rating in a research report on Saturday, March 14th. Zacks Research lowered Adherex Technologies from a “hold” rating to a “strong sell” rating in a report on Wednesday, March 25th. Finally, B. Riley Financial started coverage on Adherex Technologies in a research report on Thursday, February 12th. They set a “buy” rating and a $16.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $15.25.

Hedge Funds Weigh In On Adherex Technologies

An institutional investor recently bought a new position in Adherex Technologies stock. AQR Capital Management LLC bought a new stake in shares of Adherex Technologies Inc. (NASDAQ:FENC) during the 1st quarter, according to its most recent filing with the SEC. The fund bought 10,897 shares of the company’s stock, valued at approximately $66,000. 55.51% of the stock is currently owned by institutional investors and hedge funds.

Adherex Technologies News Roundup

Here are the key news stories impacting Adherex Technologies this week:

• Positive Sentiment: HC Wainwright is projecting positive earnings in 2027 (Q1 2027 ~$0.17, Q2 2027 ~$0.22) and raised forward-period estimates that imply recovery after current-year weakness — a bullish signal for longer‑term upside. HC Wainwright estimates / MarketBeat
• Positive Sentiment: Analysts’ consensus recommendation of “Moderate Buy” provides institutional validation and can support buying interest. Consensus Moderate Buy
• Neutral Sentiment: Director Rosty Raykov sold 10,946 shares at an average $6.31 (≈$69k), reducing his stake by 8.77%. The sale was executed under a pre‑arranged Rule 10b5‑1 plan, which typically reduces the informational significance of the trade. SEC Form 4
• Negative Sentiment: HC Wainwright trimmed near‑term and FY2026 forecasts sharply (e.g., FY2026 cut from $0.64 to $0.31; Q1 2026 cut to ($0.02) from $0.07; Q2 2026 cut to $0.05 from $0.14). Reduced near‑term earnings expectations are a clear headwind for the stock. HC Wainwright outlook
• Negative Sentiment: Recent quarterly results showed a miss (last reported EPS -$0.17 vs. est. $0.04; revenue below estimates), leaving the company operating with negative margins and a negative ROE — background weakness that amplifies sensitivity to analyst cuts. Recent results / MarketBeat

Adherex Technologies Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc and changed its name to Fennec Pharmaceuticals Inc in September 2014. Fennec Pharmaceuticals Inc was founded in 1996 and is based in Research Triangle Park, North Carolina.